BIT:RECPharmaceuticals
A Look At Recordati (BIT:REC) Valuation After Q1 2026 Results And Rare Disease Pipeline Progress
What Recordati’s latest earnings tell you about the business
Recordati Industria Chimica e Farmaceutica (BIT:REC) has put fresh first quarter numbers on the table, giving you a clearer view of how the business is performing before thinking about whether the stock still fits your portfolio.
The company reported first quarter 2026 sales of €713.42 million compared with €679.96 million a year earlier, with net income at €153.06 million versus €125.04 million. Basic earnings per share from...